ID: ALA242833

Max Phase: Preclinical

Molecular Formula: C11H12F3NO5S

Molecular Weight: 327.28

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CONC(=O)[C@H](C)c1ccc(OS(=O)(=O)C(F)(F)F)cc1

Standard InChI:  InChI=1S/C11H12F3NO5S/c1-7(10(16)15-19-2)8-3-5-9(6-4-8)20-21(17,18)11(12,13)14/h3-7H,1-2H3,(H,15,16)/t7-/m1/s1

Standard InChI Key:  FXUWZWCVZRUUJZ-SSDOTTSWSA-N

Associated Targets(Human)

Interleukin-8 receptor B 3491 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Interleukin-8 receptors, CXCR1/CXCR2 285 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Plasma 10718 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Liver microsomes 8692 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 327.28Molecular Weight (Monoisotopic): 327.0388AlogP: 1.70#Rotatable Bonds: 5
Polar Surface Area: 81.70Molecular Species: NEUTRALHBA: 5HBD: 1
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 7.70CX Basic pKa: CX LogP: 2.93CX LogD: 2.78
Aromatic Rings: 1Heavy Atoms: 21QED Weighted: 0.51Np Likeness Score: -0.65

References

1. Moriconi A, Cesta MC, Cervellera MN, Aramini A, Coniglio S, Colagioia S, Beccari AR, Bizzarri C, Cavicchia MR, Locati M, Galliera E, Di Benedetto P, Vigilante P, Bertini R, Allegretti M..  (2007)  Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.,  50  (17): [PMID:17665889] [10.1021/jm061469t]
2. Moriconi A, Bigogno C, Bianchini G, Caligiuri A, Resconi A, Dondio MG, D'Anniballe G, Allegretti M..  (2011)  Aryltriflates as a Neglected Moiety in Medicinal Chemistry: A Case Study from a Lead Optimization of CXCL8 Inhibitors.,  (10): [PMID:24900265] [10.1021/ml2001533]

Source